The JN.1 Novavax vaccine is an alternative to the LP.8.1 Pfizer-BioNTech and Moderna vaccines that were rolled out in October ...

The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...

BioNTech has completed its exchange offer to acquire CureVacAcquisition complements BioNTech’s capabilities and proprietary technologies in mRNA ...

BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

Now that two mRNA COVID-19 vaccines have been embraced as tools to end the pandemic, their developers are looking for ways to apply the technology to other diseases. They include Pfizer’s COVID ...

Messenger RNA technology leaders Moderna and BioNTech have seen their stocks rally by around 75% and 150% respectively year-to-date driven by strong demand for their Covid-19 shots and also as ...

People aiming to get its Comirnaty Covid vaccine won't need a doctor's prescription to do so. This was among several measures being considered by an advisory panel to the CDC. Investors were cheered ...

Moderna said Friday that it is suing Pfizer and BioNTech, alleging that the two companies copied Moderna's technology to make their Covid vaccine Comirnaty. "We believe that Pfizer and BioNTech ...

Even as Germany's BioNTech deals with ongoing declines of its revenue and share price, it's facing another serious concern: U.S. officials are pressing the company to pay royalties linked to the ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. BioNTech plans to return nearly €2bn to shareholders through share buybacks and a special dividend following ...

A logo of BioNTech is pictured at the headquarter of biopharmaceutical company BioNTech, one of the laboratories in the race to develop a coronavirus vaccine, in Mainz, western Germany. (Photo by Yann ...